Evidence map›Paper›PMID 29536184›Full record

ReviewCurrent neurology and neuroscience reports2018

Coccidioidal Meningitis: A Review on Diagnosis, Treatment, and Management of Complications.

Royce Johnson, Jackie Ho, Pete Fowler, Arash Heidari

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Insights into current coccidioidomycosis therapeutic pathways.Antimicrobial agents and chemotherapy · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Neurococcidiomycosis in children with hydrocephalus: assessment of functional outcome, quality of life and survival in relation to neuroimaging findings.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Royce JohnsonDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jackie HoDepartment of Pharmacy, San Leandro Hospital, 13855 E 14th St, San Leandro, CA, 94578, USA. jackie.ho@tu.edu.
Pete FowlerDepartment of Pharmacy, Kaiser Permanente, Oakland, CA, USA.
Arash HeidariDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Kern Medical Center · USKaiser Permanente · USKaiser Permanente San Leandro Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis article summarizes the diagnosis and treatment of coccidioidal meningitis (CM) and its complications. An overview of current and prospective pharmacologic treatment options and monitoring parameters is provided. A consensus has not been reached regarding universally accepted therapeutic serum levels for azoles because of insufficient evidence. We describe the preferred therapeutic drug level ranges that our institution uses to monitor azole therapy. RECENT

findingsHo et al. described the preparation and administration of intrathecally delivered amphotericin B deoxycholate. Thompson et al. described possible benefits of controversial adjuvant corticosteroid therapy for secondary prevention of vasculitic infarction secondary to CM. CM was universally fatal until the advent of intrathecal amphotericin B deoxycholate therapy, the introduction of which changed the natural history of the disease in much the same way as penicillin changed the natural history of bacterial meningitis. Although there was still significant morbidity, survival rates drastically increased to approximately 70%. The introduction of azole therapy has decreased the side effects and burden of treatment but without a significant change in CM-related mortality and morbidity compared with the use of intrathecal amphotericin B deoxycholate therapy.

Indexed as

Disease ManagementAmphotericin BAntifungal AgentsCoccidioidesCoccidioidomycosisCognitive DysfunctionDeoxycholic AcidDrug CombinationsHumansHydrocephalusInjections, SpinalMeningitisProspective StudiesTreatment OutcomeAmphotericin Bamphotericin B, deoxycholate drug combinationAntifungal AgentsDeoxycholic AcidDrug CombinationsAdjunctive corticosteroid therapyAntifungal therapyAzole therapyCoccidioidal meningitisHydrocephalusIntrathecal amphotericin B therapy

Identifiers

PMID29536184
OpenAlexW2791659277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.